<DOC>
	<DOC>NCT01372163</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after multiple doses.</brief_summary>
	<brief_title>A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy males and females of nonchildbearing potential between ages of 18 and 55 years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive. Type 2 diabetic males and females of nonchildbearing potential between ages of 18 and 55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of 7.010.0%, inclusive. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Additionally, type 2 diabetic patients who have history of diabetic complications with significant endorgan damage or pharmacologic treatment for diabetes in addition to metformin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Multiple Ascending Doses</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Type 2 Diabetic Patients</keyword>
</DOC>